Catalyst Biosciences, Inc.
(NASDAQ : CBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.53%190.531.2%$558.24m
GILDGilead Sciences, Inc.
-0.25%70.740.9%$494.49m
BIIBBiogen Inc.
-1.47%314.391.3%$441.96m
CELGCelgene Corporation
-0.84%69.651.2%$414.90m
ILMNIllumina, Inc.
-0.97%308.153.5%$394.41m
REGNRegeneron Pharmaceuticals, Inc.
-1.57%336.742.6%$277.36m
VRTXVertex Pharmaceuticals Incorporated
-3.76%163.911.9%$261.15m
ALXNAlexion Pharmaceuticals, Inc.
-1.74%116.462.0%$195.61m
AAgilent Technologies, Inc.
-1.14%63.611.5%$166.24m
EXASExact Sciences Corporation
-1.66%68.2625.3%$147.18m
LGNDLigand Pharmaceuticals Incorporated
-0.65%147.4623.3%$142.67m
SRPTSarepta Therapeutics, Inc.
-5.07%110.8516.4%$126.81m
ECYTEndocyte, Inc.
-0.04%23.572.0%$120.21m
INCYIncyte Corporation
-0.26%63.572.5%$112.11m
NKTRNektar Therapeutics
1.74%38.005.6%$107.70m

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.